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Goal-directed therapy (GDT) utilizes monitoring techniques to help guide clinicians with administering fluids,
vasopressors, inotropes, or other treatments to patients in various clinical settings. Multiple studies have
investigated the potential benefits of GDT, but no consensus on the use of GDT exists. Future trials which
address fluid and inotrope choice as well as expanding the results to evaluate patient-centered outcomes in
addition to survival are warranted.Background
Achieving hemodynamic stability during and after sur-
gery to ensure adequate perfusion and oxygenation is a
goal of every perioperative physician. We have several
types of invasive and non-invasive monitoring techniques
that influence our decisions to give intravenous fluids,
start vasopressors, or initiate inotropes on a patient. Goal-
directed therapy (GDT) utilizes these monitors to assess
cardiovascular performance and thus guides the clinician
to intervene as necessary based on a predetermined
algorithm. Many investigators have conducted studies
to examine the potential benefits of GDT in surgical
patients and also in the intensive care unit (ICU)
[1,2]. Two recent large multi-center, randomized con-
trolled trials, the Australasian Resuscitation In Sepsis
Evaluation (ARISE) and Protocolized Care for Early
Septic Shock (ProCESS) studies, examined GDT in early
septic shock [3,4]. The ARISE study found no reduction in
all-cause mortality at 90 days, and the ProCESS study
showed no improvement in outcomes including 60-day
in-hospital mortality, 90-day mortality, 1-year mortality,
or the need for organ support. A paper in Critical Care
Medicine, using a simulation model of a tertiary care hos-
pital in the United Kingdom, found a cost benefit of goal-
directed therapy. The short-term model suggested that
GDT reduced the hospital length of stay and was also
associated with fewer complications [5]. Although there* Correspondence: jboneal@bidmc.harvard.edu
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unless otherwise stated.is a vast number of publications on GDT, and a possible
cost benefit, no general consensus on the use of GDT
exists. A study published in JAMA, the Optimisation of
Cardiovascular Management to Improve Surgical Outcome
(OPTIMISE) trial, examined the effect of GDT in high-risk
gastrointestinal (GI) surgical patients on outcomes follow-
ing surgery [6].
The OPTIMISE trial was a multi-center, randomized,
observer blinded trial of 734 high risk patients under-
going major GI surgery in 17 hospitals in the United
Kingdom. The aim of the study was to evaluate a GDT al-
gorithm using intravenous fluid boluses and an inotrope
(dopexamine). Cardiac output was measured with the
LiDCO (hemodynamic monitor), and the intervention
group received non-standardized 250 cc colloid fluid bo-
luses and were started on a dopexamine infusion at a set
rate to attain an adequate stroke volume. The manage-
ment between the intervention and usual care groups was
similar except more colloid was administered in the inter-
vention group, and also the intervention group received
more blood products both during and after surgery.
The primary outcome of the study was 30-day moder-
ate or major complications and mortality. This was
present in 36.6% of the intervention group as compared
to 43.4% in the usual care group with a relative risk (RR)
of 0.84 (95% CI 0.71–1.01; p = 0.07). The primary outcome
as well as all secondary outcomes including morbidity on
day 7, infection, critical care-free days, all-cause mortality
at 30/180 days, and length of stay were not significantly
different between the groups. Thus, this study did not
confirm previous data suggesting that GDT has an out-
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guided therapy algorithm in patients undergoing major
surgery to date, and no difference was found between the
GDT group and the usual care group. A recent Cochrane
review also suggested that GDT does not reduce mortality
perioperatively; however, it may reduce complications and
hospital length of stay [1]. Interestingly, in addition to the
OPTIMISE randomized clinical trial, the group con-
ducted a systematic review which included a meta-analysis
of 38 trials. This included the same 31 studies from the
Cochrane review and added the results from OPTIMISE
and six other studies. The meta-analysis showed a reduc-
tion in complications in the intervention group versus the
control with a RR of 0.77 (95% CI 0.71–0.83; p < 0.001).
No significance was seen in hospital stay, 28-day mor-
tality, and 30-day mortality (RR 0.82, 95% CI 0.67–1.01;
p= 0.06) or mortality at the longest follow-up with 267/3,215
[8.3%] in the intervention group and 327/3,160 [10.3%] in
the control (RR 0.86, 95% CI 0.74–1.00; p = 0.06).
Although the additional studies in the Cochrane review
resulted in a statistically significant reduction of complica-
tion rates, the trials included were small, outcomes were
inconsistent, and criteria were quite diverse. Some of the
studies were conducted over a decade ago, and clinical
management is ever-changing. The fact remains that a
large, randomized trial showed no difference in mortality
when GDT was implemented into clinical care. OPTIMISE
showed a trend in the direction which supports GDT, but
more patients were likely needed to show a difference.
When including 65 patients whose care was defined as
non-adherent, the treatment effect was strengthened to a
RR 0.8 (95% CI 0.61–0.99; p = 0.04). The majority of non-
adherent patients had dopexamine administered either
lower or higher than the pre-defined set rate or received
dopexamine for less than 6 h after surgery. The trial did
not address the fact that the interventional group received
more blood products than the usual care group. This
could indicate that patients in the GDT group lost more
blood intraoperatively and may have affected the compli-
cation rate negatively.
The OPTIMISE trial and other studies on GDT are
not consistent with showing harm from this interven-
tion; however, some concerns may arise with clinicians
worried about cardiac complications in patients receiv-
ing fluid boluses and inotropic agents. A meta-analysis
reviewing cardiac complications in 22 randomized con-
trolled trials observing patients receiving GDT found a
reduction in cardiovascular complications and arrhyth-
mias, and no difference in the rate of myocardial ische-
mia or acute pulmonary edema [7]. Another study on
GDT in elderly patients with known coronary artery dis-
ease undergoing GI surgery found no difference in ad-
verse cardiac events such as congestive heart failure,
myocardial ischemia, and cardiac. This study also foundthat GDT was associated with a shorter ICU stay and time
to discharge and faster return of GI function [8]. These
findings suggest GDT to be safe when considering the po-
tential cardiac effects of introducing boluses of intraven-
ous fluid and increased cardiac demand with inotropes.
Most studies on GDT focus on initial complications
and mortality as primary and secondary endpoints. This
data may one day direct and change the standard of clin-
ical care on patients, but there are limited studies inves-
tigating patient-centered outcomes such as disability or
cognitive deficits 1 year after surgery. Long term survival
may be improved in these patients as evidenced by a
follow-up study conducted 15 years after the initial ran-
domized control trial on GDT [9]. In that study, median
survival was 3 years longer in the treatment group. With
the aging population and government focus on cutting
health-care costs, patient-centered outcomes are becom-
ing an important and worthwhile measure of clinical
care.
Conclusion
The question of whether or not GDT is truly beneficial
still remains unanswered. Assuming there is a benefit, an-
other question which needs to be addressed is the type of
fluid to administer and if the addition of an inotrope, as
well as which one, is necessary for GDT to succeed. The
algorithm varies between studies making it difficult to in-
terpret the results of meta-analyses including their data.
And what is the best hemodynamic goal to direct therapy?
Some studies assess cardiac output or stroke volume
while others use mixed venous oxygen saturation or an-
other parameter. No single hemodynamic goal or moni-
toring method has been accepted across the literature
[10]. To mention, OPTIMISE 2 is in the works with plans
to address fluid choice with or without an inotropic agent
as well as which monitor is the best option. The outcomes
may need to be broadened, and studies which include
disability-free survival at 1 year as well as other patient-
centered outcomes should be completed. Additional stud-
ies are warranted before conclusions on GDTcan be made,
and a single algorithm with which clinicians should direct
care may be difficult to universalize.
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